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Abstract
Nicotinic acetylcholine receptors (nAChRs) that contain a6 and b4 subunits have been demonstrated functionally in human
adrenal chromaffin cells, rat dorsal root ganglion neurons, and on noradrenergic terminals in the hippocampus of
adolescent mice. In human adrenal chromaffin cells, a6b4* nAChRs (the asterisk denotes the possible presence of additional
subunits) are the predominant subtype whereas in rodents, the predominant nAChR is the a3b4* subtype. Here we present
molecular and pharmacological evidence that chromaffin cells from monkey (Macaca mulatta) also express a6b4* receptors.
PCR was used to show the presence of transcripts for a6 and b4 subunits and pharmacological characterization was
performed using patch-clamp electrophysiology in combination with a-conotoxins that target the a6b4* subtype.
Acetylcholine-evoked currents were sensitive to inhibition by BuIA[T5A,P6O] and MII[H9A,L15A]; a-conotoxins that inhibit
a6-containing nAChRs. Two additional agonists were used to probe for the expression of a7 and b2-containing nAChRs.
Cells with currents evoked by acetylcholine were relatively unresponsive to the a7-selctive agonist choline but responded to
the agonist 5-I-A-85380. These studies provide further insights into the properties of natively expressed a6b4* nAChRs.
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Introduction
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion
channels that are ubiquitously expressed throughout the central
and peripheral nervous systems as well as in non neuronal tissues.
These channels are composed of five individual subunits that
assemble around a central pore and open to allow the passage of
ions across the plasma membrane when activated by an agonist
[1]. There are seventeen nAChR genes that code for the different
nAChR subunits and include ten a, four b, and one d, e, and c
subunits; receptors composed of a1b1de/c have only been found
at the neuromuscular junction. These subunits combine in various
combinations to form different receptor subtypes each having
unique biophysical properties including permeability to calcium
and sensitivity to ligands. Many of these receptor subtypes have
been implicated in human conditions. For example, receptors
containing a6 subunits are involved in disorders of the central
nervous system including Parkinson’s disease [2,3], nicotine
reward and withdrawal [4] and self-administration [5,6].
There are two main a6-containing subtypes that generally
contain b4 or b2 subunits and form the a6b4* and a6b2*
subtypes, respectively. The a6b2* subtype is thought to be
primarily expressed in the central nervous system while a6b4*
receptors are primarily found in cells of the peripheral nervous
system including rat dorsal root ganglion (DRG) neurons and
human adrenal chromaffin cells but have also been found in
mouse hippocampus [7,8,9]. Neither of these subtypes is widely
expressed and consequently less is known about their biophysical
properties and functional regulation than for other nAChR
subtypes. Investigational studies of a6-containing receptors have
been limited in part because they have proved difficult to express
in heterologous systems [10,11]. Nevertheless, functional expres-
sion in oocytes and some mammalian cell lines has been
accomplished through the construction of subunit chimeras and
concatamers [12,13,14,15].
In the central nervous system, mRNA for the a6 subunit has
been found in catecholaminergic nuclei of the rat brain [16],
particularly in midbrain dopaminergic neurons [17,18], and in the
chick retina [19]. Functional studies have shown that the release of
dopamine from dopaminergic terminals of rat [20,21] and mouse
striatal neurons [22,23] is sensitive to a-Ctx MII, an a6- and a3-
containing nAChR inhibitor. Subsequent studies using a6-
selective a-Ctxs identified the a6b2* subtype as the nAChR
responsible for modulating striatal dopamine release [24].
Additionally, in the ventral tegmental area a6-containing nAChRs
have been shown to modulate the activity of dopaminergic
neurons in the presence of ethanol or nicotine [25,26] and a6b2*
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receptors have been shown to modulate the release of GABA from
rat presynaptic GABAergic boutons [27]. In the peripheral
nervous system, a6-containing nAChRs have been shown by
electrophysiological and pharmacological analysis of recordings
from rat DRG neurons [9] and human adrenal chromaffin cells
[7] to contain the b4 subunit. In the present study we
pharmacologically evaluated acetylcholine-evoked currents from
monkey adrenal chromaffin cells and demonstrate that these
catacholaminergic cells also express a6b4* nAChRs. This is the
first report, to our knowledge, of electrophysiological recordings of
nAChR-mediated currents from primary adrenal chromaffin cells
isolated from M. mulatta.
Materials and Methods
Reagents and cRNA constructs
Stock solutions of all agonists and antagonist were made in
water. ACh, choline, amphotericin-B, and N-(2-hydroxyethyl)pi-
perazine-N’-(2-ethanesulfonic acid) (HEPES) were purchased from
Sigma Aldrich (Madrid, Spain) and 5-I-A-85380 was purchased
from Tocris Bioscience (Bristol, UK). The a-Ctxs were synthesized
as previously described [28]. The human a3, a4, b2, b3, and b4
subunit clones were provided by J. Garrett (Cognetix Inc., Salt
Lake City, UT, USA) and the a6/a3 chimera was provided by J.
Lindstrom (University of Pennsylvania, Philadelphia, PA, USA)
and subsequently subcloned into the pSGEM expression vector by
Dr. Layla Azam (University of Utah, Salt Lake City, UT, USA).
Construction of the a6/a3 subunit chimera has been previously
described and consists of an a3 subunit where the first 207 amino
acids of the ligand-binding domain were replaced with the
corresponding a6 amino acids [10]. This chimera was used
because injection of non-chimeric a6 with b2 results in few, if any,
functional receptors [10,13,29]. However, injection of b2 and b3
cRNA in conjunction with the a6/a3 chimera produces sufficient
numbers of receptors for electrophysiological recordings.
Ethics statement
Experimental procedures for obtaining monkey and mice
adrenal glands were approved by the Committee for Research
Ethics of the Universidad Auto´noma de Madrid (registry # ES-
280790000097) and conducted under the supervision of the Head
of Animal Welfare and Health in accordance with Spanish and
European guidelines (Boletı´n Oficial del Estado of March 18, 1988
and the 86/609/EEC European Council Directive). Monkey
adrenal gland mRNA was purchased from Zyagen (San Diego,
CA, USA). Oocytes were obtained from Xenopus laevis frogs.
Procedures (protocol # 11-09008) for the care and use of Xenopus
were approved by the University of Utah Institutional Animal
Care and Use Committee.
Generation of single-stranded cDNA
Total mRNA (DNAse treated) isolated from M. mulatta adrenal
gland was used to generate cDNA using the High Capacity cDNA
Reverse Transcription Kit (cat. # 4368814, Ambion, Austin, TX,
USA) following the manufacturer’s instructions. Briefly, a reaction
volume of 25 ml was used and contained 1.25 mg of mRNA. The
cycling conditions for the reverse-transcription were as follows:
step 1, 25uC for 10 min; step 2, 37uC for 120 min; and step 3,
85uC for 5 min and were achieved using a PTC-200 peltier
thermal cycler (MJ Research, Waltham, MA, USA).
Analysis of nAChRs subunits using subunit-specific
primers
Reverse-transcription polymerase chain reaction (PCR) analysis
was performed using the Qiagen Taq PCR Master Mix Kit
(Qiagen, Germantown, MD, USA) following the manufacturer’s
instructions. Briefly, 2.5 ml of cDNA template were added to the
Master Mix solution containing sense and antisense primers (final
concentration of 500 nM for each primer) for a total reaction
volume of 50 ml. Negative controls for each reaction were
performed by omission of the cDNA template and genomic
DNA contamination was assessed by performing the reaction in
the absence of the transcriptase. Primer sets for each nAChR
subunit have been previously described and were designed to
target Homo sapien sequences [30,31,32,33]. Each primer pair was
aligned with their respective nicotinic subunit target sequence to
verify compatibility with M. mulatta sequences. Full length
sequences for M. mulatta CHRNA3 and CHRNB4 were not
available in NCBI and thus, a sequence comparison for these
mRNAs was performed using the sequences of Papio anubis. The
antisense primers for CHRNA10 and CHRNB3 were found to be
mismatched and were corrected to the corresponding nucleotide
found in the M. mulatta sequence. All primers were synthesized by
the University of Utah Sequencing and Genomics Core Facility at
the University of Utah (Salt Lake City, UT, USA). The PCR was
performed in a PTC-200 thermal cycler using an initial 5 min
denaturation step at 95uC followed by 35 cycles of denaturation at
94uC for 30 s, 55–60uC for 30 s for annealing, 72uC for 45 s for
extension, with a final extension step at 72uC for 10 min.
Following PCR, the reactions were analyzed by gel (1.5% agarose
wt/vol) electrophoresis, stained and visualized with ethidum
bromide.
Verification of the amplification products
To verify amplification of the correct sequence of interest, the
bands were cut out from the gel, solubilized, and the products
purified using a QIAquick PCR Purification Kit (cat. # 21804,
Qiagen, Germantown, MD, USA) following the manufacture’s
instructions. Sequencing of the products was performed by the
University of Utah Sequencing and Genomics Core Facility. The
sequences were then subjected to BLAST analysis using NCBIs
nucleotide BLAST program.
Two-electrode voltage-clamp electrophysiology of
Xenopus laevis oocytes
Detailed methods for conducting electrophysiological experi-
ments of nAChRs heterologously expressed in Xenopus oocytes
have been previously described [34]. Briefly, stage IV-V oocytes
were injected at a 1:1 ratio with cRNA encoding cloned human
nAChR subunits a3, a4, a6/a3, b2, b3, and b4 and used 1–5 days
after injection. The oocyte membranes were clamped at a holding
potential of 270 mV and continuously gravity perfused with
standard ND96 solution buffered with HEPES and stimulated
with 1-sec pulses of 300 mM ACh or 100 mM 5-I-A-85380 once
every min. The solution changes were controlled through a series
of 3-way solenoid valves interfaced with a personal computer via a
CoolDrive valve driver (Neptune Research & Development, West
Caldwell, NJ, USA) and LabVIEW software (National Instru-
ments, Austin, TX, USA). The agonist-gated currents were
acquired using an Oocyte OC-725 series voltage-clamp amplifier
(Warner Instruments, Hamden, CT, USA), filtered through a
5 Hz low-pass Bessel filter (model F1B1; Frequency Devices,
Ottawa, IL, USA), and sampled at 50 Hz using a National
Instruments USB-6009 digital to analog converter. The toxins
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were suspended in ND96 and either perfusion applied (for
concentrations #1 mM) or applied in a static bath for 5 min (for
concentrations $10 mM).
Cell culture
Monkey chromaffin cells were obtained from two adrenal
glands of a nine years old male M. mulatta. The isolation and
culture of monkey adrenal chromaffin cells was performed as
previously described for human chromaffin cells [7]. Chromaffin
cells were isolated from adrenal glands obtained from 1–2 month
old male C57BLK6/J mice according to previously established
procedures [35]. Electrophysiology experiments were started 48 h
after plating, to allow recovery of the nicotinic receptor expression
after collagenase treatment [36], and were continued for 5 days ex
vivo. The inherent difficulties of obtaining M. mulatta glands limited
the number of experiments that could be performed.
Electrophysiological recordings from adrenal chromaffin
cells
Electrophysiology recordings were performed in the perforated-
patch configuration using the patch-clamp technique. The
external solution used to record nicotinic currents was (in mM):
2 CaCl2, 145 NaCl, 5.5 KCl, 1 MgCl2, 10 HEPES, and 10 D-
glucose; the pH was adjusted to 7.4 with NaOH. The intracellular
solution composition was (in mM): 145 K-glutamate, 8 NaCl, 1
MgCl2, 10 HEPES, and 0.5 mg/ml amphotericin B; the pH was
adjusted to 7.2 with KOH. An amphotericin B stock solution was
prepared daily at a concentration of 50 mg/ml in dimethylsulph-
oxide and kept protected from light. The final concentration of
amphotericin B was prepared by sonicating 10 ml of stock
amphotericin B in 1 ml of internal solution. Pipettes were dipped
in amphotericin-free intracellular solution for several seconds and
then back-filled with freshly mixed intracellular solution contain-
ing amphotericin. Patch pipettes were pulled from borosilicate
glass capillary tubes, partially coated with wax then heat polished
and had resistances of 2–3 MV when filled with the internal
solution. After seal formation and perforation, only recordings in
which the access resistance of the pipette and the leak current were
#20 MV and #20 pA, respectively, were accepted for analysis;
series resistance was compensated up to 80%. A HEKA EPC10
amplifier (HEKA Elektronic, Lambrecht, Germany) was used to
record agonist-evoked currents. The recordings were acquired at
holding potential of 280 mV and filtered through a 4-pole Bessel
filter at 2.9 kHz. The sampling frequency used was 10 kHz.
The perfusion system for drug application consisted of a multi-
barreled polyethylene pipette positioned close to the cell under
study. The agonist used were ACh (300 mM), choline (10 mM),
and 5-I-A-85380 (100 mM) and always delivered from separate
tubes. The cells were stimulated with 200 ms pulses of agonists
once every three minutes. The antagonists were continuously
perfused between pulses and this flow was only interrupted during
agonist perfusion.
Data analysis
Data analysis of electrophysiological recordings from monkey
and mouse chromaffin cells was performed using using IGOR Pro
software (Wavemetrics, Lake Oswego, OR, USA) and GraphPad
Prism software (La Jolla, CA, USA). Concentration-response
analyses of ACh-gated currents from X. laevis oocytes and all other
statistical analyses were performed using GraphPad Prism.
Concentration-response curves for inhibition of ACh-gated
currents were generated by fitting the data to the Hill equation:
% response = 100/(1 +([toxin]/IC50)nH). The confidence intervals
for the a-Ctx IC50 values are given in parenthesis. All statistical
analyses of current amplitudes and densities are shown as the
mean 6 S.E.M. unless otherwise specified. Each data set was
assessed for Gaussian distribution and only those that passed
normality tests (a= 0.05) were analyzed for significance by
comparing the percent block by the toxins to a theoretical value
of 100%, i.e. control values, using a one sample t-test. Data sets
that did not pass tests for normality were subjected to a non
parametric alternative where indicated.
Results
The nAChR agonists ACh and 5-I-A-85380 but not
choline, evoke currents in monkey chromaffin cells
We began our investigation of isolated cells obtained from the
adrenal glands of M. mulatta monkey by testing three different
nAChR agonists, ACh, choline, and 5-I-A-85380. Choline is a full
agonist of heterologously expressed M. mulatta a7 nAChRs [37]
and is considered to be a7-selective and can be used to assay for
the presence of a7 receptors when multiple nAChR subtypes are
potentially expressed in a given cell. The compound 5-I-A-85380
has high affinity for heteromeric receptor subtypes that contain the
b2 subunit [38] and was chosen with the expectation that
receptors that contain this subunit would be preferentially
activated. Acetylcholine (300 mM) evoked currents with average
peak amplitudes of 865 6 387 pA (n = 18;6= S.D.M; Fig. 1). In
four of these cells, 10 mM choline evoked currents with
amplitudes that were, on average, only 1.760.1% of the responses
evoked by 300 mM ACh or 2164 pA versus 12456238 pA,
respectively, in the same cells (Fig. 2A-C). The insensitivity to
choline indicated that the ACh-evoked responses were mediated
by a heteromeric nAChR subtype and that there were few
nAChRs of the a7 subtype. Next we determined if the cells were
responsive to the agonist 5-I-A-85380. As shown in Fig. 2D-F,
100 mM 5-I-A-85380 evoked currents with amplitudes that were,
on average, 170616% larger than the currents evoked by ACh or
10886120 pA versus 6576 97 pA, respectively (n = 4). The current
densities were also larger for those evoked by 5-I-A-85380
compared to those evoked by ACh or 256628 pA/pF versus
149622 pA/pF, respectively (Fig. 2G; n = 4). This difference was
not statistically significant indicating that the effect was not due to
Figure 1. Acetylcholine evokes currents in monkey adrenal
chromaffin cells. Scatter plot showing the current amplitudes evoked
by 300 mM ACh. The dashed line denotes the mean and the error bars
denote the S.D.M; n = 18.
doi:10.1371/journal.pone.0094142.g001
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differences in cell size. These results suggest that receptors
containing the b2 subunit may also be present but at high
concentrations of 5-I-A-85380 receptors containing the b4 subunit
could potentially be activated [39]. The activation by both ACh
and 5-I-A-85380, but not choline, suggested that the dominant
nAChR subtype(s) expressed in monkey adrenal chromaffin cells
contained either b2 and/or b4 subunits. However, based on the
pharmacological profile of the receptors found in human and
rodents, we hypothesized that these receptors were likely to be
a3b4* or a6b4* nAChRs.
PCR analysis of monkey adrenal gland mRNA
demonstrates the presence of multiple nAChR subunit
transcripts
nAChRs vary significantly in terms of the number of possible
subtypes that a given cell may express. In rodent chromaffin cells,
the predominant nAChR is the a3b4* subtype [7,40] but in
contrast, in human the predominant subtype is an a6b4* nAChR
[7]. Thus, in order to guide the pharmacological analysis of the
nAChR currents present in monkey chromaffin cells, we performed
PCR analysis of total mRNA obtained from M. mulatta adrenal
gland. The primers used to assay for the various nAChR subunit
transcripts are provided in Table 1. As shown in Fig. 3A-C,
transcripts for a6, a3, b2 and b4 were detected as well as transcripts
for other nAChR subunits. Reactions performed in the absence of
cDNA template were always negative (Fig. 3A-C).
a-Contoxins MII[H9A,L15A] and BuIA[T5A,P6O]
distinguish among nAChR subtypes
Some a-Ctxs and their synthetic analogs show a remarkable
ability to distinguish among the various nAChR subtypes. These
small peptides are derived from the venom of marine cone snails
that use them to capture their prey. Two of these peptides, a-Ctxs
MII [28] and BuIA [41], are widely used to identify native
Figure 2. Representative trace recordings of agonist-evoked currents frommonkey adrenal chromaffin cells. A and B, Current traces of
ACh- and choline-evoked currents from a single cell. C, Quantitative comparison of the current amplitudes evoked by each respective agonist.
Responses to 10 mM choline were compared to the average responses evoked by 300 mM ACh in the same cells; the error bars denote the S.E.M.
(n = 4) and the asterisks denote statistical significance (***p,0.0001) as determined by a one sample t-test. D and E, Current traces of ACh- and 5-I-A-
85380-evoked currents from a single cell. F, Quantitative comparison of the current amplitudes evoked by each respective agonist. Responses to
100 mM 5-I-A-85380 were compared to the average responses evoked by 300 mM ACh in the same cells; the error bars denote the S.E.M. (n = 4) and
asterisk denote statistical significance (*p,0.05) as determined by a one sample t-test. G, The current amplitudes shown in F were normalized to
membrane capacitance and shown as an expression of current density in pA/pF. The differences between the current densities produced by the two
agonists were not statistically significant as determined by a Wilcoxon signed rank test (p=0.0625).
doi:10.1371/journal.pone.0094142.g002
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receptors. Synthetic analogs of these a-Ctxs have been developed
with increased specificity for a6-containing over a3-containing
nAChRs. An analog of MII, MII[H9A,L15A], distinguishes
between rat a6/a3b4 and a3b4, being more potent on the a6/
a3b4 subtype [42], and BuIA[T5A,P6O], an analog of BuIA,
distinguishes between rat and mouse a6/a3b4 and a6/a3b2b3
receptors, being more potent on the a6/a3b4 subtype [8]. Since
the activity of these a-Ctx analogs on primate receptors had not
been previously quantified, we tested them on heterologously
expressed human receptors in X. laevis oocytes and determined
their IC50 values. MII[H9A,L15A] inhibited ACh-evoked re-
sponses mediated by a6/a3b4 receptors with an IC50 value of 13.3
(9.7–18.1) nM (Fig. 4A). This value was 100-fold lower than the
1.4 (1.1–1.7) mM value obtained for a3b4 nAChRs (Fig. 4B). Next
we tested BuIA[T5A,P6O] on the a6/a3b4 and a6/a3b2b3
subtypes. This BuIA analog was .900-fold more potent at
inhibiting a6/a3b4 versus a6/a3b2b3 nAChRs (IC50 values of
11.1 (9.1–13.6) nM versus .10 mM, respectively). Thus, MII[-
H9A,L15A] can be used to distinguish between a6b4* and a3b4*
nAChRs and BuIA[T5A,P6O] can be used to distinguish between
a6b4* and a6b2* nAChRs. We also tested MII[H9A,L15A] and
BuIA[T5A,P6O] on non a6-containing human nAChR subtypes
including a3b2, a4b2, a4b4 and found that both toxins showed
very limited activity on these receptors subtypes (Fig. 4A,B).
a-Ctxs MII[H9A,L15A] and BuIA[T5A,P6O] potently inhibit
ACh-evoked currents in monkey chromaffin cells
To pharmacologically determine the nAChR subtype mediating
the ACh-evoked currents in monkey chromaffin cells, we started
by using MII[H9A,L15A] at 100 nM, a concentration where little,
if any, inhibition of a3b4* receptors would be expected, followed
by a concentration of 1 mM. At a concentration of 100 nM, this
MII analog inhibited the ACh-evoked responses by 7462% (n = 5)
Figure 3. PCR analysis of the nAChR subunit transcripts
present in monkey adrenal gland. A-C, PCR products for the
nAChR subunits a2–a7, a9, a10, and b2–b4 were analyzed by agarose
gel electrophoresis and visualized using ethidum bromide fluorescence.
Negative controls for each reaction were performed by omission of the
cDNA template and the results are shown in the lanes immediately to
the right for each respective subunit.
doi:10.1371/journal.pone.0094142.g003
Table 1. PCR primers.
Target Primer Sequence Size Temp. References
a2 59-GTGGAGGAGGAGGACAGA-39 (s) 155 bp 58 uC [31]
59-CTTCTGCATGTGGGGTGATA-39 (as)
a3 59-CAAGCAACGAGGGCAACG-39 (s) 121 bp 60 uC [32]
59-CCGTCCTGGCAGGGGTAG-39 (as)
a4 59-GTTCCATGACGGGCGGGTGCAGTGGACT-39 (s) 482 bp 60 uC [32]
59-GGGATGACCAGTGAGGTGGACGGGATGAT-39 (as)
a5 59-TTTCTTCACACGCTTCCCAAA-39 (s) 179 bp 60 uC [32]
59-TCACGGACATCATTTTCCTTCA-39 (as)
a6 59-TCCATCGTGGTGACTGTGT-39 (s) 125 bp 58 uC [31]
59-AGGCCACCTCATCAGCAG-39 (as)
a7 59-GGGAACCTGCTGTACATCGGC-39 (s) 115 bp 60 uC [32]
59-GGTGCTCATCGTGCGTGGG-39 (as)
a9 59-GTCCAGGGTCTTGTTTGT-39 (s) 403 bp 55 uC [33]
59-ATCCGCTCTTGCTATGAT-39 (as)
a10 59-CTGTTCCGTGACCTCTTCG-39 (s) 388 bp 60 uC Present Work
59-GAAGGCCGCCACGTCCA-39 (as)
b2 59-CAGCTCATCAGTGTGCA-39 (s) 347 bp 55 uC [33]
59-GTGCGGTCGTAGGTCCA-39 (as)
b3 59-TGGGGAGTACCTGCTGTTCA-39 (s) 385 bp 58 uC [30] Present Work
59-CGGCATAATTGGGAATACCA-39 (as)
b4 59-AGCAAGTCATGCGTGACCAAG-39 (s) 210 bp 60 uC [32]
59-GCTGACACCTTCTAATGCCTCC-39 (as)
doi:10.1371/journal.pone.0094142.t001
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Figure 4. Concentration-response analysis of the inhibition of cloned human nAChRs expressed in X. laevis oocytes by a-Ctxs
MII[H9A,L15A] and BuIA[T5A,P6O]. Oocytes expressing the indicated nAChRs were subjected to TEVC as described in ‘‘Materials and Methods’’
and the IC50 values for inhibition of the responses to ACh by each a-Ctx analog determined by fitting the data to the Hill equation. A, MII[H9A,L15A]
inhibited a6/a3b4 with an IC50 value of 13.3 (9.7–18.1) nM (n= 4) and a3b4 with an IC50 value of 1.4 (1.1–1.7) mM (n= 4). Compared to controls, the
responses after a 5 min exposure to 10 mM toxin were 4264% (n= 7) for a3b2, 9365% (n= 7) for a4b2, and 10161% (n = 4) for a4b4 receptors. B,
BuIA[T5A,P6O] inhibited a6/a3b4 with an IC50 value of 11.1 (9.1–13.6) nM and a6/a3b2b3 with an IC50 value .10 mM. The responses after a 5 min
exposure to 10 mM toxin were 10264% (n= 4) for a3b2, 10262% (n = 4) for a4b2, and 7465% (n = 5) for a4b4 receptors. For clarity, the symbols for
inhibition of a3b2 and a4b2 receptors are shown staggered to avoid overlap.
doi:10.1371/journal.pone.0094142.g004
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Figure 5. a-Ctx MII[H9A,L15A] and BuIA[T5A,P6O] potently inhibit the ACh-evoked currents in monkey chromaffin cells. A,
Representative trace recordings of ACh-evoked currents and the inhibition by 100 nM and 1 mM MII[H9A,L15A]. B, Quantitative analysis of the
inhibition by 100 nM (n= 5) and 1 mM MII[H9A,L15A] (n = 4). Error bars show average values 6 S.E.M (n = 5); asterisks denote statistical significance
(***p,0.001) as determined by a one sample t-test. C,D, Trace recordings of ACh-evoked currents and the inhibition by 100 nM and 1 mM
BuIA[T5A,P6O]. E, Quantitative analysis of the inhibition by 100 nM (n= 2) and 1 mM BuIA[T5A,P6O] (n = 4); error bars show average values 6 S.E.M.
doi:10.1371/journal.pone.0094142.g005
Figure 6. a-Ctx MII[H9A,L15A] inhibits ACh-evoked responses less potently in mouse adrenal chromaffin cells. A, Representative trace
recordings of ACh-evoked currents and the inhibition by 100 nM and 1 mM MII[H9A,L15A]. B, Quantitative analysis of the inhibition by 100 nM (n= 6)
and 1 mM MII[H9A,L15A] (n = 6). Statistical analysis of the inhibition by 100 nM indicated no statistical significance compared to control responses
(p.0.05) but significance for 1 mM (p,**0.01); error bars show average values 6 S.E.M.
doi:10.1371/journal.pone.0094142.g006
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and at 1 mM the responses were almost completely abolished
(9760.4% inhibition; n = 4) (Fig. 5A,B). Next we tested BuIA[-
T5A,P6O], also at 100 nM and 1 mM, to selectively inhibit a6b4*
versus a6b2* nAChRs. The ACh-evoked responses were inhibited
by 8164% (n = 2) at 100 nM and by 9860.4% (n = 4) at 1 mM
(Fig. 5 C-E). As an additional test of the specificity of
MII[H9A,L15A] for the a6b4 subtype over the a3b4 subtype,
we tested the toxin on mouse chromaffin cells that have been
reported to lack mRNA for the a6 subunit [43] and thus the
receptors expressed by these cells are likely to be mainly a3b4*
nAChRs. As shown in Fig. 6, in the presence of 100 nM
MII[H9A,L15A], the average response to ACh was 9662%
(n = 6) of control responses and in the same cells the responses in
the presence of 1 mM were on average 6266% (n = 6) of controls.
These data indicate that the nAChRs expressed in M. mulatta
adrenal chromaffin cells are a6b4* nAChRs.
5-I-A-85380 activates monkey chromaffin cell a6b4*
nAChRs
As shown in Fig. 2D-F, the efficacy of 100 mM 5-I-A-85380 in
evoking currents was greater than 300 mM ACh in cells that were
sequentially stimulated with both agonists. Although 5-I-A-85380
has high affinity for receptors containing the b2 subunit, at
100 mM receptors containing the b4 subunit may also be
activated. To determine if 100 mM 5-I-A-85380 could activate
a6b4* nAChRs, we tested this compound on heterologously
expressed human a6/a3b4 receptors in Xenopus oocytes and found
that at 100 mM this compound activated currents that were on
average 100612.1% (n = 4; Fig. S1) of the amplitude produced by
300 mM ACh in the same cells. Additionally, inhibition of 5-I-A-
85380-evoked currents in monkey chromaffin cells by BuIA[-
T5A,P6O] would also suggest that this agonist activates a6b4*
nAChRs. Indeed, perfusion with 1 mM BuIA[T5A,P6O] almost
completely abolished the 5-I-A-85380-evoked currents (9560.4%
inhibition; n = 4) (Fig. 7A,B). Thus 5-I-A-85380 shows high
efficacy in activating the nAChRs in monkey chromaffin cells
and the inhibition of these currents by BuIA[T5A,P6O] indicated
that they were mediated by the a6b4* subtype and not by
nAChRs containing two axb2 ligand binding sites.
Discussion
In this work we provide the first report of the molecular and
pharmacological characterization of the nAChRs expressed by
monkey adrenal chromaffin cells. Initial studies demonstrated that
the nAChRs in these cells could be activated by ACh and 5-I-A-
85380 but not choline (Fig. 2A-F). These results suggested that the
dominant receptor expressed was a heteromeric nAChR subtype.
PCR analysis of monkey adrenal gland mRNA demonstrated the
presence of transcripts for multiple nAChR subunits including a2–
a7, a9, and b2–b4 but not a10 (Fig 3A-C). Subsequent
pharmacological analysis of the agonist-evoked currents was
performed using a-Ctxs that selectively target the a6/a3b4
receptor over the a6/a3b2b3 and a3b4 subtypes as determined
in Xenopus oocytes (Fig. 4A, B). In monkey chromaffin cells,
substantial inhibition of the ACh-evoked currents was achieved
using a submaximal concentration (100 nM) of MII[H9A,L15A]
(Fig. 5A,B), an antagonist that, as shown in Figure 4A, is .100-
fold more potent on human a6/a3b4 receptors than a3b4
receptors. Substantial inhibition was also achieved using 100 nM
BuIA[T5A,P6O] (Fig. 5C,E) which is .900-fold more potent on
a6/a3b4 receptors than a6/a3b2b3 receptors (Fig. 4B). Complete
inhibition of the ACh-evoked currents was achieved using a
concentration of 1mM MII[H9A,L15A] or BuIA[T5A,P6O]
(Fig. 5A,B and 5D,E). In mouse chromaffin cells, that likely only
express a3b4*, much less inhibition was observed by MII[-
H9A,L15A] lending further support to our conclusion that
monkey chromaffin cells predominantly express a6b4* nAChRs.
Thus, when taken together the molecular and pharmacological
evidence presented here support the presence of a nAChR in
Figure 7. BuIA[T5A,P6O] inhibits 5-I-A-85380-evoked currents
in monkey chromaffin cells. A, Representative trace recordings of 5-
I-A-85380-evoked currents and the inhibition by 1 mM BuIA[T5A,P6O]. B,
Quantitative analysis of the inhibition by 1 mM BuIA[T5A,P6O] (n = 4);
error bars show average values 6 S.E.M.
doi:10.1371/journal.pone.0094142.g007
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monkey chromaffin cells that contains a6 and b4 subunits and that
the receptor composed of these subunits, the a6b4* subtype,
predominates. We note, however, that these experiments do not
rule out the possible presence of additional subunits such as a5, b2,
or b3, that are known to assemble with the a6 subunit [44], or
homomeric a7 nAChRs. Previously in human chromaffin cells, we
found that a7 nAChRs contribute only ,7% to the whole-cell
current under electrophysiological conditions similar to those used
in the current study and that positive identification was only
possible using selective a7 agonists and positive allosteric
modulators to prevent desensitization [45]. These compounds
may also be useful in future studies to determine if a7 nAChRs are
also functionally expressed in monkey chromaffin cells.
We also observed that the nAChR agonist 5-I-A-85380 at
100 mM was more efficacious than 300 mM ACh at activating
monkey chromaffin cell nAChRs (Fig 2D-G) and as efficacious as
300 mM ACh when tested on human a6/a3b4 nAChRs expressed
in Xenopus oocytes (Fig. S1). This ligand was initially described as
an axb2-selective ligand but was later shown to also activate other
non b2-containing nAChRs [38,39]. In this report we have shown
that 5-I-A-85380 also activates heterologously expressed human
a6/a3b4 as well as native monkey a6b4* nAChRs as evidenced
by the fact that currents evoked by this compound in monkey cells
could be fully inhibited by 1 mM BuIA[T5A,P6O] (Fig. 6A,B).
The presence of multiple discrete agonist and/or antagonist
binding sites in a single nAChR complex can be challenging to
detect in functional assays. There are two putative agonist binding
sites in a given axbx receptor complex and gating of the channel is
thought to require the binding of two agonist molecules [1,46].
Thus, an agonist that shows selectivity for ax-b2 binding sites
would not be expected to activate receptors that contain both ax-
b4 and ax-b2 binding sites. In contrast, a single antagonist ligand
of nAChRs is sufficient for inhibition of agonist-evoked responses
therefore, the simplest interpretation of the data presented here is
that the nAChRs in monkey chromaffin cells contain at least one
a6-b4 ligand binding interface. Nevertheless, future studies using
radiolabeled ligands and immunoprecipitation to assay for the
presence of additional subunits is warranted.
Although the a6 and a3 subunits are highly homologous and
receptors composed of these subunits often have similar pharma-
cological properties with respect to agonist and antagonist
sensitivities in some cases large differences can be observed. For
example, it was recently reported that some analogs of a-Ctx PeIA
show a 15,000-fold difference in the IC50 values for heterologously
Figure 8. Sequence alignment of monkey and human a6 nAChR subunits. A, Sequence alignment of monkey and human a6 subunits
identified a single residue in the extracellular ligand-binding domain at position 100 that differed between the two species. The asterisks identify
residues that have previously shown to be important for a-Ctx binding [47,48,49]. Note that these residues are strictly conserved between the two
species. TM indicates the transmembrane domains.
doi:10.1371/journal.pone.0094142.g008
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expressed rat a6/a3b2b3 versus a3b2 nAChRs [47]. This differ-
ence was shown to be attributed to three amino acids that differ
between the a6 and a3 ligand binding domains. Differences in
amino acid composition of the same subunit between species can
also affect ligand potencies. A comparative study between human
and monkey showed that there are minor differences in the
sensitivity of heterologously expressed a7 receptors to agonists but
not to antagonists even though the ligand binding domains
between the two species differ by only two amino acids [37]. We
performed a sequence alignment between monkey and human a6
subunits and found that in the ligand-binding domain there is a
single amino acid difference at position 100 (Fig. 8); in monkey this
residue is a glutamine whereas in human it is a glutamate. This
single amino acid difference is not likely to affect the binding of the
a-Ctxs used in this study, however, because the critical residues of
the a6 subunits that interact with the a-Ctxs are strictly conserved
across monkey, human, and rodent species. These residues, E152,
D184, and T195, have been previously identified as the critical
residues that confer high affinity binding of MII- and BuIA-related
a-Ctxs to heterologously expressed a6-containing nAChRs
[47,48,49]. Thus, the potencies obtained in this report for
heterologously expressed human a6-containing nAChRs are likely
to match those of native monkey a6-containing nAChRs. Indeed,
the values obtained for inhibition of monkey a6b4* nAChRs by
100 nM and 1 mM MII[H9A,L15A] and BuIA[T5A,P6O] closely
match the values obtained for human a6/a3b4 nAChRs in
oocytes (Fig. 5A-E, and 4A,B, respectively). We also performed a
sequence alignment of other human and monkey nAChR subunits
and note that the sequences of the b2 extracellular ligand binding
domains differ by a single amino acid at position 165 where there
is a conservative aspartate to glutamate difference between
monkey and human, respectively (data not shown). Unfortunately,
complete sequences for M. mulatta a3 and b4 subunits are not
available in NCBI for analysis. However, a comparison between
human and baboon (Papio anubis) a3 revealed that the amino acids
in the positions important for a-Ctx binding are also shared
between these two species.
Coexpression of a6 and b4 subunits appears to be limited to a
few discrete areas in the nervous system. In rodents, immunopre-
cipitation studies have demonstrated that a6 and b4 subunits are
present in the retina [50] and studies that utilized PCR analysis
showed that a6 and b4 subunits may be expressed in neurons of
the ventral tegmental area and DRG neurons [9,27,51,52]. In M.
mulatta, in situ hybridization studies of brain slices found a6 and b4
coexpression in the lateral part of the medial habenula [53].
Electrophysiological recordings of a6b4* nAChR currents have
only been demonstrated in rat DRG neurons [9], in human
adrenal chromaffin cells [7], and in M. mulatta chromaffin cells as
shown in the present study. In human chromaffin cells, a6b4*
nAChRs are the predominant nAChR subtype expressed in
contrast to what is found in rodent chromaffin cells where the
nAChRs that predominate are a3b4* nAChRs [7,40]. As in
human chromaffin cells, a6b4* nAChRs also appear to dominate
in monkey chromaffin cells. Thus, there is a species difference
between primates and rodents in terms of nAChR expression by
chromaffin cells.
Ligands that target a6b2* nAChRs have been proposed as
potential pharmacological agents for the treatment of several
human conditions including Parkinson’s and nicotine dependence
[54,55]. However, ligands that target a6b2* would need to be
devoid of activity on the a6b4* subtype to avoid potential
cardiovascular side effects caused by alternations in the release of
catecholamines from the adrenal gland. Our study provides
valuable insights into the pharmacology of a6b4* nAChRs in
catecholaminergic cells and validate chromaffin cells as a
particularly promising system for the study of native a6b4*
nAChRs.
Supporting Information
Figure S1 The activity of 5-I-A-85380 on a6/a3b4
nAChRs. Human a6/a3b4 nAChRs were expressed in Xenopus
laevis oocytes and subjected to two-electrode voltage-clamp
electrophysiology as described in ‘‘Materials and Methods’’. The
responses to 100 mM 5-I-A-85380 were normalized to the
responses to 300 mM ACh obtained in the same cells. The
responses to 5-I-A-85380 were on average 100612% of those
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